Pfenex (Pfenex) Net Margin % : -1,322.79% (As of Jun. 2020)

View and export this data going back to 2014. Start your Free Trial

What is Pfenex Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Pfenex's Net Income for the three months ended in Jun. 2020 was $-10.33 Mil. Pfenex's Revenue for the three months ended in Jun. 2020 was $0.78 Mil. Therefore, Pfenex's net margin for the quarter that ended in Jun. 2020 was -1,322.79%.

The historical rank and industry rank for Pfenex's Net Margin % or its related term are showing as below:

PFNX' s Net Margin % Range Over the Past 10 Years
Min: -294.44 Med: -61.67 Max: 9.11
Current: -20.71

PFNX's Net Margin % is not ranked
in the Biotechnology industry.
Industry Median: -162.58 vs PFNX: -20.71

Pfenex Net Margin % Historical Data

The historical data trend for Pfenex's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfenex Net Margin % Chart

Pfenex Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Net Margin %

Get a 7-Day Free Trial

-294.44

9.11

-89.24

-266.49

2.10

Pfenex Quarterly Data
	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20
Net Margin %	Get a 7-Day Free Trial															-269.26	20.21	42.30	-1,488.42	-1,322.79

Competitive Comparison of Pfenex's Net Margin %

For the Biotechnology subindustry, Pfenex's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pfenex's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pfenex's Net Margin % distribution charts can be found below:

* The bar in red indicates where Pfenex's Net Margin % falls into.

Pfenex Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Pfenex's Net Margin for the fiscal year that ended in Dec. 2019 is calculated as

Net Margin	=	Net Income (A: Dec. 2019 )	/	Revenue (A: Dec. 2019 )
	=	1.058	/	50.326
	=	2.10 %

Pfenex's Net Margin for the quarter that ended in Jun. 2020 is calculated as

Net Margin	=	Net Income (Q: Jun. 2020 )	/	Revenue (Q: Jun. 2020 )
	=	-10.331	/	0.781
	=	-1,322.79 %

Pfenex (AMEX:PFNX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Pfenex Net Margin % Related Terms

Thank you for viewing the detailed overview of Pfenex's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pfenex (Pfenex) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pfenex Inc (AMEX:PFNX) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

10790 Roselle Street, San Diego, CA, USA, 92121

Website

https://www.pfenex.com

Pfenex Inc is a clinical-stage biotechnology company involved in the development of protein production and bioanalytic technology. The biosimilars portfolio include PF582, for the treatment of patients with retinal diseases; PF530, designed to treat patients with multiple sclerosis; and PF708, to treat osteoporosis patients at high risk of fractures. Its vaccine portfolio consists of Px563L, a novel anthrax vaccine candidate to meet U.S. government demand, funded by the U.S. Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority.

Executives

Ligand Pharmaceuticals Inc	10 percent owner	3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121
Phillip M Schneider	director	GEN-PROBE INCORPORATED, 10210 GENETIC CENTER DRIVE, SAN DIEGO CA 92121
Jason Grenfell-gardner	director	105 LINCOLN AVENUE BUENA NJ 08310
Patrick K. Lucy	officer: Chief Business Officer	C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Robin Campbell	director	C/O PFENEX INC., 10790 ROSELLE STREET SAN DIEGO CA 92121
Magda Marquet	director	ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
John Mack Taylor	director	C/O PFENEX, INC. 10790 ROSELLE STREET SAN DIEGO CA 92121
Evert B. Schimmelpennink	director, officer: See Remarks	C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Shawn Scranton	officer: Chief Operating Officer	C/O PFENEX INC 10790 ROSELLE STREET SAN DIEGO CA 92121
Martin Brenner	officer: Chief Scientific Officer	C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Lorianne Masuoka	director	C/O PFENEX INC. 10790 ROSELLE STREET SAN DIEGO CA 92121
Newtyn Management, Llc	10 percent owner	60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Weiss Asset Management Lp	10 percent owner	222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Andrew M Weiss	10 percent owner	222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Wam Gp Llc	10 percent owner	222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116